APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Peptide APIs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Therapeutic Peptide APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174040770327 December 2025191 pages

Choose your research edition.

Industry ResearchTherapeutic Peptide APIs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Peptide APIs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal Therapeutic Peptide APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Peptide APIs Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Peptide APIs Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Therapeutic Peptide APIs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Therapeutic Peptide APIs include AmbioPharm, Aspen API, Bachem, Bio Basic, CordenPharma, CPC Scientific, GenScript, JPT Peptide Technologies and Limitless Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Therapeutic Peptide APIs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Peptide APIs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Peptide APIs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Peptide APIs market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Peptide APIs Segment by Company

AmbioPharm

Aspen API

Bachem

Bio Basic

CordenPharma

CPC Scientific

GenScript

JPT Peptide Technologies

Limitless Biotech

Lonza

Piramal Pharma

PolyPeptide

ScinoPharm

Syngene

USV Peptides

Hybio Pharmaceutical

Guangdong Jianyuan Pharmaceutical

Jiangsu Sinopep-Allsino Biopharmaceutical

Zhejiang Peptites Biotech

Cheng Du Sheng Nuo Biotec

Hainan Shuangcheng Pharmaceuticals

Therapeutic Peptide APIs Segment by Type

Bioactive Peptides

Synthetic Peptides

Therapeutic Peptide APIs Segment by Application

Pharmaceuticals

Scientific Research

Other

Therapeutic Peptide APIs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide APIs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Peptide APIs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Therapeutic Peptide APIs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Therapeutic Peptide APIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Therapeutic Peptide APIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Peptide APIs Industry Trends Table 2. Therapeutic Peptide APIs Industry Drivers Table 3. Therapeutic Peptide APIs Industry Opportunities and Challenges Table 4. Therapeutic Peptide APIs Industry Restraints Table 5. Global Therapeutic Peptide APIs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Therapeutic Peptide APIs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Therapeutic Peptide APIs Sales by Manufacturers (Tons) & (2021-2026) Table 8. Global Therapeutic Peptide APIs Sales Market Share by Manufacturers Table 9. Global Therapeutic Peptide APIs Average Sales Price (US$/K G) of Manufacturers (2021-2026) Table 10. Global Therapeutic Peptide APIs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Therapeutic Peptide APIs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Therapeutic Peptide APIs Manufacturers, Product Type & Application Table 13. Global Therapeutic Peptide APIs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Therapeutic Peptide APIs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Bioactive Peptides Table 17. Major Manufacturers of Synthetic Peptides Table 18. Global Therapeutic Peptide APIs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 19. Global Therapeutic Peptide APIs Sales by Type (2021-2026) & (Tons) Table 20. Global Therapeutic Peptide APIs Sales by Type (2027-2032) & (Tons) Table 21. Global Therapeutic Peptide APIs Sales Market Share by Type (2021-2026) Table 22. Global Therapeutic Peptide APIs Sales Market Share by Type (2027-2032) Table 23. Global Therapeutic Peptide APIs Revenue by Type 2021 VS 2025 VS 2032 (Tons) Table 24. Global Therapeutic Peptide APIs Revenue by Type (2021-2026) & (Tons) Table 25. Global Therapeutic Peptide APIs Revenue by Type (2027-2032) & (Tons) Table 26. Global Therapeutic Peptide APIs Revenue Market Share by Type (2021-2026) Table 27. Global Therapeutic Peptide APIs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Pharmaceuticals Table 29. Major Manufacturers of Scientific Research Table 30. Major Manufacturers of Other Table 31. Global Therapeutic Peptide APIs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 32. Global Therapeutic Peptide APIs Sales by Application (2021-2026) & (Tons) Table 33. Global Therapeutic Peptide APIs Sales by Application (2027-2032) & (Tons) Table 34. Global Therapeutic Peptide APIs Sales Market Share by Application (2021-2026) Table 35. Global Therapeutic Peptide APIs Sales Market Share by Application (2027-2032) Table 36. Global Therapeutic Peptide APIs Revenue by Application 2021 VS 2025 VS 2032 (Tons) Table 37. Global Therapeutic Peptide APIs Revenue by Application (2021-2026) & (Tons) Table 38. Global Therapeutic Peptide APIs Revenue by Application (2027-2032) & (Tons) Table 39. Global Therapeutic Peptide APIs Revenue Market Share by Application (2021-2026) Table 40. Global Therapeutic Peptide APIs Revenue Market Share by Application (2027-2032) Table 41. Global Therapeutic Peptide APIs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 42. Global Therapeutic Peptide APIs Sales by Region (2021-2026) & (Tons) Table 43. Global Therapeutic Peptide APIs Sales Market Share by Region (2021-2026) Table 44. Global Therapeutic Peptide APIs Sales Forecasted by Region (2027-2032) & (Tons) Table 45. Global Therapeutic Peptide APIs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 47. North America Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 48. North America Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 49. Europe Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 50. Europe Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 51. Europe Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 52. Asia Pacific Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 53. Asia Pacific Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 54. Asia Pacific Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 55. South America, Middle East and Africa Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. South America, Middle East and Africa Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 57. South America, Middle East and Africa Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 58. Global Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Therapeutic Peptide APIs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Therapeutic Peptide APIs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Therapeutic Peptide APIs Revenue Market Share by Region (2021-2026) Table 62. Global Therapeutic Peptide APIs Revenue Market Share by Region (2027-2032) Table 63. AmbioPharm Company Information Table 64. AmbioPharm Business Overview Table 65. AmbioPharm Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AmbioPharm Therapeutic Peptide APIs Product Portfolio Table 67. AmbioPharm Recent Development Table 68. Aspen API Company Information Table 69. Aspen API Business Overview Table 70. Aspen API Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Aspen API Therapeutic Peptide APIs Product Portfolio Table 72. Aspen API Recent Development Table 73. Bachem Company Information Table 74. Bachem Business Overview Table 75. Bachem Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bachem Therapeutic Peptide APIs Product Portfolio Table 77. Bachem Recent Development Table 78. Bio Basic Company Information Table 79. Bio Basic Business Overview Table 80. Bio Basic Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Bio Basic Therapeutic Peptide APIs Product Portfolio Table 82. Bio Basic Recent Development Table 83. CordenPharma Company Information Table 84. CordenPharma Business Overview Table 85. CordenPharma Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. CordenPharma Therapeutic Peptide APIs Product Portfolio Table 87. CordenPharma Recent Development Table 88. CPC Scientific Company Information Table 89. CPC Scientific Business Overview Table 90. CPC Scientific Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. CPC Scientific Therapeutic Peptide APIs Product Portfolio Table 92. CPC Scientific Recent Development Table 93. GenScript Company Information Table 94. GenScript Business Overview Table 95. GenScript Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. GenScript Therapeutic Peptide APIs Product Portfolio Table 97. GenScript Recent Development Table 98. JPT Peptide Technologies Company Information Table 99. JPT Peptide Technologies Business Overview Table 100. JPT Peptide Technologies Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio Table 102. JPT Peptide Technologies Recent Development Table 103. Limitless Biotech Company Information Table 104. Limitless Biotech Business Overview Table 105. Limitless Biotech Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Limitless Biotech Therapeutic Peptide APIs Product Portfolio Table 107. Limitless Biotech Recent Development Table 108. Lonza Company Information Table 109. Lonza Business Overview Table 110. Lonza Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Lonza Therapeutic Peptide APIs Product Portfolio Table 112. Lonza Recent Development Table 113. Piramal Pharma Company Information Table 114. Piramal Pharma Business Overview Table 115. Piramal Pharma Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Piramal Pharma Therapeutic Peptide APIs Product Portfolio Table 117. Piramal Pharma Recent Development Table 118. PolyPeptide Company Information Table 119. PolyPeptide Business Overview Table 120. PolyPeptide Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. PolyPeptide Therapeutic Peptide APIs Product Portfolio Table 122. PolyPeptide Recent Development Table 123. ScinoPharm Company Information Table 124. ScinoPharm Business Overview Table 125. ScinoPharm Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. ScinoPharm Therapeutic Peptide APIs Product Portfolio Table 127. ScinoPharm Recent Development Table 128. Syngene Company Information Table 129. Syngene Business Overview Table 130. Syngene Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Syngene Therapeutic Peptide APIs Product Portfolio Table 132. Syngene Recent Development Table 133. USV Peptides Company Information Table 134. USV Peptides Business Overview Table 135. USV Peptides Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. USV Peptides Therapeutic Peptide APIs Product Portfolio Table 137. USV Peptides Recent Development Table 138. Hybio Pharmaceutical Company Information Table 139. Hybio Pharmaceutical Business Overview Table 140. Hybio Pharmaceutical Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio Table 142. Hybio Pharmaceutical Recent Development Table 143. Guangdong Jianyuan Pharmaceutical Company Information Table 144. Guangdong Jianyuan Pharmaceutical Business Overview Table 145. Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio Table 147. Guangdong Jianyuan Pharmaceutical Recent Development Table 148. Jiangsu Sinopep-Allsino Biopharmaceutical Company Information Table 149. Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview Table 150. Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio Table 152. Jiangsu Sinopep-Allsino Biopharmaceutical Recent Development Table 153. Zhejiang Peptites Biotech Company Information Table 154. Zhejiang Peptites Biotech Business Overview Table 155. Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio Table 157. Zhejiang Peptites Biotech Recent Development Table 158. Cheng Du Sheng Nuo Biotec Company Information Table 159. Cheng Du Sheng Nuo Biotec Business Overview Table 160. Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio Table 162. Cheng Du Sheng Nuo Biotec Recent Development Table 163. Hainan Shuangcheng Pharmaceuticals Company Information Table 164. Hainan Shuangcheng Pharmaceuticals Business Overview Table 165. Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales (Tons), Price (US$/K G), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio Table 167. Hainan Shuangcheng Pharmaceuticals Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Therapeutic Peptide APIs Distributors List Table 171. Therapeutic Peptide APIs Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Therapeutic Peptide APIs Product Image Figure 2. Global Therapeutic Peptide APIs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Peptide APIs Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Peptide APIs Sales (2021-2032) & (Tons) Figure 5. Global Therapeutic Peptide APIs Average Price (US$/K G) & (2021-2032) Figure 6. Global Top 5 and 10 Therapeutic Peptide APIs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Bioactive Peptides Image Figure 9. Synthetic Peptides Image Figure 10. Global Therapeutic Peptide APIs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 11. Global Therapeutic Peptide APIs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Therapeutic Peptide APIs Sales Market Share by Type (2021-2032) Figure 13. Global Therapeutic Peptide APIs Revenue by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global Therapeutic Peptide APIs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Therapeutic Peptide APIs Revenue Market Share by Type (2021-2032) Figure 16. Pharmaceuticals Image Figure 17. Scientific Research Image Figure 18. Other Image Figure 19. Global Therapeutic Peptide APIs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 20. Global Therapeutic Peptide APIs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Therapeutic Peptide APIs Sales Market Share by Application (2021-2032) Figure 22. Global Therapeutic Peptide APIs Revenue by Application (2021 VS 2025 VS 2032) & (Tons) Figure 23. Global Therapeutic Peptide APIs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Therapeutic Peptide APIs Revenue Market Share by Application (2021-2032) Figure 25. North America Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 26. North America Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 27. U.S. Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 28. Canada Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 29. Mexico Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 30. Europe Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 31. Europe Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 32. Germany Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 33. France Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 34. U.K. Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 35. Italy Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 36. Netherlands Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 37. Asia Pacific Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 38. Asia Pacific Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 39. China Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 40. Japan Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 41. South Korea Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 42. Southeast Asia Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 43. India Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 44. Australia Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 45. South America, Middle East and Africa Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 46. South America, Middle East and Africa Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 47. Brazil Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 48. South Africa Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 49. Saudi Arabia Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 50. Turkey Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 51. Argentina Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 52. UAE Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 53. Egypt Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 54. Chile Therapeutic Peptide APIs Sales and Growth Rate (2021-2032) & (Tons) Figure 55. Global Therapeutic Peptide APIs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Therapeutic Peptide APIs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Therapeutic Peptide APIs Revenue (2021-2032) & (US$ Million) Figure 58. North America Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Therapeutic Peptide APIs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Therapeutic Peptide APIs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Therapeutic Peptide APIs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Therapeutic Peptide APIs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Therapeutic Peptide APIs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Bioactive Peptides
  • Synthetic Peptides
Applications
  • Pharmaceuticals
  • Scientific Research
  • Other
Companies covered
  • AmbioPharm
  • Aspen API
  • Bachem
  • Bio Basic
  • CordenPharma
  • CPC Scientific
  • GenScript
  • JPT Peptide Technologies
  • Limitless Biotech
  • Lonza
  • Piramal Pharma
  • PolyPeptide
  • ScinoPharm
  • Syngene
  • USV Peptides
  • Hybio Pharmaceutical
  • Guangdong Jianyuan Pharmaceutical
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • Zhejiang Peptites Biotech
  • Cheng Du Sheng Nuo Biotec
  • Hainan Shuangcheng Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Therapeutic Peptide APIs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Therapeutic Peptide APIs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Therapeutic Peptide APIs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Therapeutic Peptide APIs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Therapeutic Peptide APIs Market Dynamics
  1. 2.1 Therapeutic Peptide APIs Industry Trends
  2. 2.2 Therapeutic Peptide APIs Industry Drivers
  3. 2.3 Therapeutic Peptide APIs Industry Opportunities and Challenges
  4. 2.4 Therapeutic Peptide APIs Industry Restraints
3 Therapeutic Peptide APIs Market by Manufacturers
  1. 3.1 Global Therapeutic Peptide APIs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Therapeutic Peptide APIs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Therapeutic Peptide APIs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Therapeutic Peptide APIs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Therapeutic Peptide APIs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Therapeutic Peptide APIs Manufacturers, Product Type & Application
  7. 3.7 Global Therapeutic Peptide APIs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Therapeutic Peptide APIs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Therapeutic Peptide APIs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Therapeutic Peptide APIs Tier 1, Tier 2, and Tier 3
4 Therapeutic Peptide APIs Market by Type
  1. 4.1 Therapeutic Peptide APIs Type Introduction
  2. 4.1.1 Bioactive Peptides
  3. 4.1.2 Synthetic Peptides
  4. 4.2 Global Therapeutic Peptide APIs Sales by Type
  5. 4.2.1 Global Therapeutic Peptide APIs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Therapeutic Peptide APIs Sales by Type (2021-2032)
  7. 4.2.3 Global Therapeutic Peptide APIs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Therapeutic Peptide APIs Revenue by Type
  9. 4.3.1 Global Therapeutic Peptide APIs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Therapeutic Peptide APIs Revenue by Type (2021-2032)
  11. 4.3.3 Global Therapeutic Peptide APIs Revenue Market Share by Type (2021-2032)
5 Therapeutic Peptide APIs Market by Application
  1. 5.1 Therapeutic Peptide APIs Application Introduction
  2. 5.1.1 Pharmaceuticals
  3. 5.1.2 Scientific Research
  4. 5.1.3 Other
  5. 5.2 Global Therapeutic Peptide APIs Sales by Application
  6. 5.2.1 Global Therapeutic Peptide APIs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Therapeutic Peptide APIs Sales by Application (2021-2032)
  8. 5.2.3 Global Therapeutic Peptide APIs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Therapeutic Peptide APIs Revenue by Application
  10. 5.3.1 Global Therapeutic Peptide APIs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Therapeutic Peptide APIs Revenue by Application (2021-2032)
  12. 5.3.3 Global Therapeutic Peptide APIs Revenue Market Share by Application (2021-2032)
6 Global Therapeutic Peptide APIs Sales by Region
  1. 6.1 Global Therapeutic Peptide APIs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Peptide APIs Sales by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Peptide APIs Sales by Region (2021-2026)
  4. 6.2.2 Global Therapeutic Peptide APIs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Therapeutic Peptide APIs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Therapeutic Peptide APIs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Therapeutic Peptide APIs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Therapeutic Peptide APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Therapeutic Peptide APIs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Therapeutic Peptide APIs Revenue by Region
  1. 7.1 Global Therapeutic Peptide APIs Revenue by Region
  2. 7.1.1 Global Therapeutic Peptide APIs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Therapeutic Peptide APIs Revenue by Region (2021-2026)
  4. 7.1.3 Global Therapeutic Peptide APIs Revenue by Region (2027-2032)
  5. 7.1.4 Global Therapeutic Peptide APIs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Therapeutic Peptide APIs Revenue (2021-2032)
  8. 7.2.2 North America Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Therapeutic Peptide APIs Revenue (2021-2032)
  11. 7.3.2 Europe Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Therapeutic Peptide APIs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Therapeutic Peptide APIs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Therapeutic Peptide APIs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AmbioPharm
  2. 8.1.1 AmbioPharm Company Information
  3. 8.1.2 AmbioPharm Business Overview
  4. 8.1.3 AmbioPharm Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AmbioPharm Therapeutic Peptide APIs Product Portfolio
  6. 8.1.5 AmbioPharm Recent Developments
  7. 8.2 Aspen API
  8. 8.2.1 Aspen API Company Information
  9. 8.2.2 Aspen API Business Overview
  10. 8.2.3 Aspen API Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aspen API Therapeutic Peptide APIs Product Portfolio
  12. 8.2.5 Aspen API Recent Developments
  13. 8.3 Bachem
  14. 8.3.1 Bachem Company Information
  15. 8.3.2 Bachem Business Overview
  16. 8.3.3 Bachem Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bachem Therapeutic Peptide APIs Product Portfolio
  18. 8.3.5 Bachem Recent Developments
  19. 8.4 Bio Basic
  20. 8.4.1 Bio Basic Company Information
  21. 8.4.2 Bio Basic Business Overview
  22. 8.4.3 Bio Basic Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio Basic Therapeutic Peptide APIs Product Portfolio
  24. 8.4.5 Bio Basic Recent Developments
  25. 8.5 CordenPharma
  26. 8.5.1 CordenPharma Company Information
  27. 8.5.2 CordenPharma Business Overview
  28. 8.5.3 CordenPharma Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CordenPharma Therapeutic Peptide APIs Product Portfolio
  30. 8.5.5 CordenPharma Recent Developments
  31. 8.6 CPC Scientific
  32. 8.6.1 CPC Scientific Company Information
  33. 8.6.2 CPC Scientific Business Overview
  34. 8.6.3 CPC Scientific Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CPC Scientific Therapeutic Peptide APIs Product Portfolio
  36. 8.6.5 CPC Scientific Recent Developments
  37. 8.7 GenScript
  38. 8.7.1 GenScript Company Information
  39. 8.7.2 GenScript Business Overview
  40. 8.7.3 GenScript Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GenScript Therapeutic Peptide APIs Product Portfolio
  42. 8.7.5 GenScript Recent Developments
  43. 8.8 JPT Peptide Technologies
  44. 8.8.1 JPT Peptide Technologies Company Information
  45. 8.8.2 JPT Peptide Technologies Business Overview
  46. 8.8.3 JPT Peptide Technologies Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio
  48. 8.8.5 JPT Peptide Technologies Recent Developments
  49. 8.9 Limitless Biotech
  50. 8.9.1 Limitless Biotech Company Information
  51. 8.9.2 Limitless Biotech Business Overview
  52. 8.9.3 Limitless Biotech Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Limitless Biotech Therapeutic Peptide APIs Product Portfolio
  54. 8.9.5 Limitless Biotech Recent Developments
  55. 8.10 Lonza
  56. 8.10.1 Lonza Company Information
  57. 8.10.2 Lonza Business Overview
  58. 8.10.3 Lonza Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lonza Therapeutic Peptide APIs Product Portfolio
  60. 8.10.5 Lonza Recent Developments
  61. 8.11 Piramal Pharma
  62. 8.11.1 Piramal Pharma Company Information
  63. 8.11.2 Piramal Pharma Business Overview
  64. 8.11.3 Piramal Pharma Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Piramal Pharma Therapeutic Peptide APIs Product Portfolio
  66. 8.11.5 Piramal Pharma Recent Developments
  67. 8.12 PolyPeptide
  68. 8.12.1 PolyPeptide Company Information
  69. 8.12.2 PolyPeptide Business Overview
  70. 8.12.3 PolyPeptide Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PolyPeptide Therapeutic Peptide APIs Product Portfolio
  72. 8.12.5 PolyPeptide Recent Developments
  73. 8.13 ScinoPharm
  74. 8.13.1 ScinoPharm Company Information
  75. 8.13.2 ScinoPharm Business Overview
  76. 8.13.3 ScinoPharm Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ScinoPharm Therapeutic Peptide APIs Product Portfolio
  78. 8.13.5 ScinoPharm Recent Developments
  79. 8.14 Syngene
  80. 8.14.1 Syngene Company Information
  81. 8.14.2 Syngene Business Overview
  82. 8.14.3 Syngene Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Syngene Therapeutic Peptide APIs Product Portfolio
  84. 8.14.5 Syngene Recent Developments
  85. 8.15 USV Peptides
  86. 8.15.1 USV Peptides Company Information
  87. 8.15.2 USV Peptides Business Overview
  88. 8.15.3 USV Peptides Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 USV Peptides Therapeutic Peptide APIs Product Portfolio
  90. 8.15.5 USV Peptides Recent Developments
  91. 8.16 Hybio Pharmaceutical
  92. 8.16.1 Hybio Pharmaceutical Company Information
  93. 8.16.2 Hybio Pharmaceutical Business Overview
  94. 8.16.3 Hybio Pharmaceutical Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio
  96. 8.16.5 Hybio Pharmaceutical Recent Developments
  97. 8.17 Guangdong Jianyuan Pharmaceutical
  98. 8.17.1 Guangdong Jianyuan Pharmaceutical Company Information
  99. 8.17.2 Guangdong Jianyuan Pharmaceutical Business Overview
  100. 8.17.3 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio
  102. 8.17.5 Guangdong Jianyuan Pharmaceutical Recent Developments
  103. 8.18 Jiangsu Sinopep-Allsino Biopharmaceutical
  104. 8.18.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
  105. 8.18.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
  106. 8.18.3 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio
  108. 8.18.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
  109. 8.19 Zhejiang Peptites Biotech
  110. 8.19.1 Zhejiang Peptites Biotech Company Information
  111. 8.19.2 Zhejiang Peptites Biotech Business Overview
  112. 8.19.3 Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio
  114. 8.19.5 Zhejiang Peptites Biotech Recent Developments
  115. 8.20 Cheng Du Sheng Nuo Biotec
  116. 8.20.1 Cheng Du Sheng Nuo Biotec Company Information
  117. 8.20.2 Cheng Du Sheng Nuo Biotec Business Overview
  118. 8.20.3 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio
  120. 8.20.5 Cheng Du Sheng Nuo Biotec Recent Developments
  121. 8.21 Hainan Shuangcheng Pharmaceuticals
  122. 8.21.1 Hainan Shuangcheng Pharmaceuticals Company Information
  123. 8.21.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  124. 8.21.3 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio
  126. 8.21.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Therapeutic Peptide APIs Value Chain Analysis
  2. 9.1.1 Therapeutic Peptide APIs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Therapeutic Peptide APIs Production Mode & Process
  6. 9.2 Therapeutic Peptide APIs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Therapeutic Peptide APIs Distributors
  9. 9.2.3 Therapeutic Peptide APIs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst